Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.35 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.35 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25896412 | 1.00 | HTT (0.47) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL25957558 | 1.00 | HTT (0.47) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL30002762 | 0.98 | HTT (0.50) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL15923111 | 0.98 | HTT (0.45) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL25957567 | 0.98 | HTT (0.50) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL15923100 | 0.92 | HTT (0.47) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17309230 | 0.92 | HTT (0.47) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL16218386 | 0.90 | HTT (0.50) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL15923216 | 0.90 | HTT (0.41) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL31749577 | 0.90 | HTT (0.50) | HTTMEN1THRBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638477-B | Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230241057-A1 | COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI | UNIVERSITE PARIS 13 PARIS-NORD (FR) | 2023-08-03 | — | — | US | disclosed |
| CN-110637022-B | Pyrrolopyrimidine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-112638477-A | Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-110637022-A | Pyrrolopyrimidine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2019-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241057-A1 | COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI | SERPINC1, PLAT, F2 | HTT 429/4885MEN1 1004/4885THRB 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.